Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
491.60    -7.80 (-1.56%)
Bid:
491.00
Ask:
491.60
Spread: 0.60 (0.122%)
Market Cap: £1.33b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

AGM Update

20 Feb 2026 07:00

RNS Number : 7427T
Chemring Group PLC
20 February 2026
 

FOR IMMEDIATE RELEASE 20 FEBRUARY 2026

 

CHEMRING GROUP PLC ("Chemring", the "Group" or the "Company")

AGM Update

Chemring, a key contributor to the defence industrial base, supplying materials, subsystems, components, and technologies into growing areas of defence, security, and space markets, issues the following update ahead of its Annual General Meeting taking place later today.

Key points:

· FY26 outlook in line with the Board's expectations.

· Order book at 30 January 2026 of £1,364m (30 January 2025: £1,351m).

· Q1 order intake of £122m (Q1 FY25 £393m). Orders received across both sectors as well as a £22.5m STORM Missile Defence Centre order for Roke received post 30 January 2026.

· Expected FY26 revenue 85% covered by Q1 revenues and current order book (30 January 2025: 81%). Outer years cover continuing to build with strong order pipeline.

 

Michael Ord, Group Chief Executive, commented:

"Chemring is well positioned to benefit from rising defence spending across NATO and allied nations, evidenced by our record order book and a strong pipeline of opportunities, and we will continue to invest in our business to capture further growth. For FY26 our outlook is unchanged."

Current Trading and Outlook 

The Group's outlook for FY26 remains in line with the Board's expectations with a H2 weighting slightly heavier than the prior year.

We have had a slightly slower than anticipated start to the year, primarily due to some operational disruption in countermeasures production, which is now largely resolved. At our US countermeasures facility, Kilgore Flares ("KFL") in Tennessee, the operational performance and efficiency of its fully automated facility continues to steadily ramp. The decision has therefore been taken to retire a number of KFL's legacy operations and to transfer manufacturing to the automated facility, which is expected to lead to a non-cash impairment charge.

Whilst there continues to be disruption in the UK market due to the delayed publication of the UK's Defence Investment Plan, order intake has slightly improved in recent months and the medium-term outlook for sustained defence spending remains strong.

Significant investment in growing Energetics capacity continues at pace. This investment, which is being funded through existing debt facilities, is expected to result in net debt trending higher at H1 and the full year as we invest in the business.

In June 2025 the Norwegian Government announced that the feasibility study into the establishment of a second production facility to further increase the production of military explosives had moved to the second phase. This concept selection phase will determine the design and size of the facility, along with regulatory and commercial arrangements. The Norwegian Government will provide up to £16m in funding towards the costs of this study, which is due to conclude by the end of 2026.

The Group's order book at 30 January 2026 was £1,364m (30 January 2025: £1,351m). Having started the financial year with order cover of 76%, the Group's expected FY26 revenue is now 85% (30 January 2025: 81%) covered by revenue generated in the period to date and the current order book.

Order intake since 31 October 2025 was £122m (30 January 2025: £393m) against a very strong prior year comparator period in which several multi-year contracts were won by both sectors.

The Countermeasures & Energetics ("C&E") sector's FY26 revenue is now 96% covered by revenue generated in the period to date and the current order book, having started the year with 95% cover (30 January 2025: 98%).

Of note, Chemring Countermeasures UK won contracts from a range of NATO and non-NATO customers totalling £55m for the delivery of airborne and naval countermeasures, with deliveries scheduled during FY26-FY29, further improving visibility.

In the Sensors & Information ("S&I") sector, Roke has continued to make good progress on key strategic activities receiving c.£45m of orders in the year to date, including the receipt of a £22.5m order relating to the STORM Missile Defence Centre contract, which was received in the period since 30 January 2026.

Having started the year with 45% cover, the S&I sector's FY26 expected revenue at 30 January 2026 was 52% covered by revenue generated in the period to date and the current order book (30 January 2025: 54%). Order intake within S&I has progressed as expected during the current financial year.

Board of Directors

As previously announced, Fiona MacAulay, Senior Independent Director, will not be seeking re-election at today's Annual General Meeting. The process to identify a suitable candidate to replace her is progressing well. In the meantime, Stephen King, Non-Executive Director, has been appointed the Interim Senior Independent Director. Stephen will fulfil this role in addition to his role as Chair of the Audit Committee.

- ENDS -

 

For further information:

 

Rupert Pittman Group Director of Corporate Affairs, 01794 463401

Chemring Group PLC

 

James McFarlane MHP Group 07584 142665

Ollie Hoare 07817 458804

 

 

 

Cautionary statement

This announcement may contain forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements. There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are: increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects. Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

Notes to editors

 

· Chemring is a FTSE-250 global business that specialises in the manufacture of high technology products and the provision of services to the aerospace, defence and security markets

· Employing approximately 2,700 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is organised under two strategic product segments: Sensors & Information and Countermeasures & Energetics

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development ("R&D"), Chemring has the agility to rapidly react to urgent customer needs

 

www.chemring.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMGPUMCPUPQGRB
Date   Source Headline
7th Aug 20237:00 amRNSTransaction in Own Shares
4th Aug 20234:16 pmRNSDirector/PDMR Shareholding
4th Aug 20234:15 pmRNSDirector/PDMR Shareholding
4th Aug 20237:00 amRNSTransaction in Own Shares
3rd Aug 20237:00 amRNSTransaction in Own Shares
2nd Aug 20237:00 amRNSTransaction in Own Shares
1st Aug 20239:26 amRNSTotal Voting Rights
1st Aug 20237:00 amRNSShare buyback programme
3rd Jul 20237:00 amRNSDirector/PDMR Shareholding
21st Jun 20239:47 amRNSBlock listing Interim Review
13th Jun 20237:00 amRNSAppointment of non-executive director
6th Jun 20237:00 amRNSHalf year results to 30 April 2023
1st Jun 202310:28 amRNSTotal Voting Rights
24th May 20237:00 amRNSAppointment of Chief Financial Officer
2nd May 20232:51 pmRNSTotal Voting Rights
20th Apr 202312:02 pmRNSDirector Declaration
3rd Apr 20239:25 amRNSTotal Voting Rights
29th Mar 20237:00 amRNSContract Award
28th Mar 20233:29 pmRNSHolding(s) in Company
16th Mar 20234:23 pmRNSDoc re. Ordinary & Special Resolutions
15th Mar 20233:11 pmRNSResult of AGM
15th Mar 20237:00 amRNSAGM Trading Update
1st Mar 202310:33 amRNSTotal Voting Rights
24th Feb 20239:07 amRNSDirector Declaration
1st Feb 202310:10 amRNSTotal Voting Rights
24th Jan 20233:09 pmRNSDirector/PDMR Shareholding
23rd Jan 20237:00 amRNSDirectorate Change
16th Jan 202310:44 amRNSNotice of AGM
9th Jan 20237:10 amRNSDirector Declaration
3rd Jan 202310:54 amRNSTotal Voting Rights
20th Dec 20227:00 amRNSDirector/PDMR Shareholding
20th Dec 20227:00 amRNSDirector/PDMR Shareholding
20th Dec 20227:00 amRNSDirector/PDMR Shareholding
19th Dec 20223:41 pmRNSBlock listing Interim Review
14th Dec 202212:31 pmRNSDirector/PDMR Shareholding
14th Dec 202212:28 pmRNSDirector/PDMR Shareholding
14th Dec 202212:27 pmRNSDirector/PDMR Shareholding
14th Dec 202212:25 pmRNSDirector/PDMR Shareholding
14th Dec 202212:23 pmRNSDirector/PDMR Shareholding
14th Dec 202212:20 pmRNSDirector/PDMR Shareholding
13th Dec 20227:00 amRNSFinal Results
1st Dec 202210:01 amRNSTotal Voting Rights
11th Nov 20222:30 pmRNSHolding(s) in Company
1st Nov 202210:02 amRNSTotal Voting Rights
18th Oct 20224:17 pmRNSHolding(s) in Company
6th Oct 20227:00 amRNSTrading Update
3rd Oct 20221:55 pmRNSAdditional Listings
3rd Oct 20229:36 amRNSTotal Voting Rights
12th Sep 20229:00 amRNSNotice of Results
1st Sep 20229:13 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.